Advances in medical treatment of Cushing’s disease

References

• Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab.88(12), 5593–5602 (2003).
   PubMed Web of Science ®Google Scholar
• Bourdeau I, Bard C, Forget H, Boulanger Y, Cohen H, Lacroix A. Cognitive function and cerebral assessment in patients who have Cushing’s syndrome. Endocrinol. Metab. Clin. North Am.34(2), 357–369 (2005).
   PubMed Web of Science ®Google Scholar
• Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing’s syndrome. Pituitary7(4), 253–256 (2004).
   PubMedGoogle Scholar
• Mancini T, Doga M, Mazziotti G, Giustina A. Cushing’s syndrome and bone. Pituitary7(4), 249–252 (2004).
   PubMedGoogle Scholar
• Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey Group. J. Clin. Endocrinol. Metab.80(11), 3114–3120 (1995).
   PubMed Web of Science ®Google Scholar
• Hammer GD, Tyrrell JB, Lamborn KR et al. Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J. Clin. Endocrinol. Metab.89(12), 6348–6357 (2004).
   PubMed Web of Science ®Google Scholar
• Hofmann BM, Fahlbusch R. Treatment of Cushing’s disease: a retrospective clinical study of the latest 100 cases. Front. Horm. Res.34, 158–184 (2006).
   PubMed Web of Science ®Google Scholar
• Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing’s disease: the need for long-term surveillance. Clin. Endocrinol. (Oxford)63(5), 549–559 (2005).
   PubMed Web of Science ®Google Scholar
• Castinetti F, Nagai M, Dufour H et al. γ knife radiosurgery is a successful adjunctive treatment in Cushing’s disease. Eur. J. Endocrinol.156(1), 91–98 (2007).
   PubMed Web of Science ®Google Scholar
• Gumbs AA, Gagner M. Laparoscopic adrenalectomy. Best Pract. Res. Clin. Endocrinol. Metab.20(3), 483–499 (2006).
   PubMed Web of Science ®Google Scholar
• Assie G, Bahurel H, Coste J et al. Corticotroph tumor progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. J. Clin. Endocrinol. Metab.92(1), 172–179 (2007).
   PubMed Web of Science ®Google Scholar
• Miller JW, Crapo L. The medical treatment of Cushing’s syndrome. Endocr. Rev.14(4), 443–458 (1993).
   PubMed Web of Science ®Google Scholar
• Sonino N, Boscaro M. Medical therapy for Cushing’s disease. Endocrinol. Metab. North Am.28, 211–222 (1999).
   PubMed Web of Science ®Google Scholar
• Nieman LK. Medical therapy of Cushing’s disease. Pituitary5(2), 77–82 (2002).
   PubMedGoogle Scholar
• Morris D, Grossman A. The medical management of Cushing’s syndrome. Ann. NY Acad. Sci.970, 119–133 (2002).
   PubMed Web of Science ®Google Scholar
• Sonino N, Boscaro M, Fallo F. Pharmacologic management of Cushing syndrome. Treat. Endocrinol.4(2), 87–94 (2005).
   Google Scholar
• Trincali G, Aubry JM, Moscianese K et al. Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission. J. Psychiatry Neurosci.29(6), 459–466 (2004).
   Google Scholar
• Krieger DT, Amorosa L, Linick F. Cyproheptadine-induced remission of Cushing’s disease. N. Engl. J. Med.293(18), 893–896 (1975).
   PubMed Web of Science ®Google Scholar
• Sonino N, Fava GA, Fallo F, Franceschetto A, Belluardo P, Boscaro M. Effect of the serotonin antagonists ritanserin and ketanserin in Cushing’s disease. Pituitary3(2), 55–59 (2000).
   PubMedGoogle Scholar
• Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat. Med.8(11), 1281–1287 (2002).
   PubMed Web of Science ®Google Scholar
• Emery MN, Leontiou C, Bonner SE et al. PPAR-γ expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-γ receptor. Clin. Endocrinol. (Oxford)65(3), 389–395 (2006).
   PubMed Web of Science ®Google Scholar
• Heaney AP. Novel medical approaches for the treatment of Cushing’s disease. J. Endocrinol. Invest.27(6), 591–595 (2004).
   PubMed Web of Science ®Google Scholar
• Ambrosi B, Dall’Asta C, Cannavo S et al. Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing’s disease. Eur. J. Endocrinol.151(2), 173–178 (2004).
   PubMed Web of Science ®Google Scholar
• Giraldi FP, Scaroni C, Arvat E et al. Effect of protracted treatment with rosiglitazone, a PPAR-γ agonist, in patients with Cushing’s disease. Clin. Endocrinol. (Oxford)64(2), 219–224 (2006).
   PubMed Web of Science ®Google Scholar
• Cannavo S, Arosio M, Almoto B, Dall’Asta C, Ambrosi B. Effectiveness of long-term rosiglitazone administration in patients with Cushing’s disease. Clin. Endocrinol. (Oxford)63(1), 118–119 (2005).
   PubMed Web of Science ®Google Scholar
• Cannavo S, Ambrosi B, Chiodini I et al. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-γ ligand, rosiglitazone, in Cushing’s disease. J. Endocrinol. Invest.27(5), RC8–R11 (2005).
   Web of Science ®Google Scholar
• Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing’s disease. J. Clin. Endocrinol. Metab.90(3), 1340–1346 (2005).
   PubMed Web of Science ®Google Scholar
• Barbaro D, Lapi P, Orsini P, Pasquini C, Ciaccio S. Pioglitazone treatment in Cushing’s disease. J. Endocrinol. Invest.28(4), 388–389 (2005).
   PubMed Web of Science ®Google Scholar
• Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB. The PPAR-γ activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson’s syndrome. Clin. Endocrinol. (Oxford)64(5), 519–522 (2006).
   PubMed Web of Science ®Google Scholar
• Munir A, Song F, Ince P, Walters SJ, Ross R, Newell-Price J. Ineffectiveness of rosiglitazone therapy in Nelson’s syndrome. J. Clin. Endocrinol. Metab.92(5), 1758–1763 (2007).
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, de Herder WW. Dopamine receptor expression and function in corticotroph pituitary tumors. J. Clin. Endocrinol. Metab.89(5), 2452–2462 (2004).
   PubMed Web of Science ®Google Scholar
• T’Sjoen G, Defeyter I, Van De Saffele J, Rubens R, Vandeweghe M. Macroprolactinemia associated with Cushing’s disease, successfully treated with cabergoline. J. Endocrinol. Invest.25(2), 172–175 (2002).
   PubMed Web of Science ®Google Scholar
• Miyoshi T, Otsuka F, Takeda M et al. Effect of cabergoline treatment on Cushing’s disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J. Endocrinol. Invest.27(11), 1055–1059 (2004).
   PubMed Web of Science ®Google Scholar
• Illouz F, Dubois-Ginouves S, Laboureau S, Rohmer V, Rodien P. Use of cabergoline in persisting Cushing’s disease. Ann. Endocrinol. (Paris)67(4), 353–356 (2006).
   PubMed Web of Science ®Google Scholar
• Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline. J. Endocrinol. Invest.22(11), 860–865 (1999).
   PubMed Web of Science ®Google Scholar
• Casulari LA, Naves LA, Mello PA, Pereira Neto A, Papadia C. Nelson’s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm. Res.62(6), 300–305 (2004).
   PubMed Web of Science ®Google Scholar
• Godbout A, Beauregard H, Babin S, Sabourin A, Lacroix A. Cabergoline in the long-term treatment of Cushings disease. Proceedings of the Endocrine Society’s 89th Annual Meeting. Toronto, Canada, 2–5 June 2007 (Abstract P4–51).
   Google Scholar
• Pivonello R, De Martino MC, Faggiano A et al. Cabergoline treatment in Cushings disease: effect on hypertension, glucose intolerance and dyslipidemia. Proceedings of the Endocrine Society’s 89th Annual Meeting. Toronto, Canada, 2–5 June 2007 (Abstract P4-50).
   Google Scholar
• Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med.356(1), 39–46 (2007).
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med.356(1), 29–38 (2007).
   PubMed Web of Science ®Google Scholar
• Roth BL. Drugs and valvular heart disease. N. Engl. J. Med.356(1), 6–9 (2007).
   PubMed Web of Science ®Google Scholar
• van der Hoek J, Lamberts SW, Hofland LJ. The role of somatostatin analogs in Cushing’s disease. Pituitary7(4), 257–264 (2004).
   PubMedGoogle Scholar
• Arnaldi G, Polenta B, Cardinaletti M, Boscaro M. Potential indications for somatostatin analogs in Cushing’s syndrome. J. Endocrinol. Invest.28(11 Suppl. International), 106–110 (2005).
   PubMed Web of Science ®Google Scholar
• Vignati F, Loli P. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J. Clin. Endocrinol. Metab.81(8), 2885–2890 (1996).
   PubMed Web of Science ®Google Scholar
• Stalla GK, Brockmeier SJ, Renner U et al. Octreotide exerts different effects in vivo and in vitro in Cushing’s disease. Eur. J. Endocrinol.2, 125–131 (1994).
   Google Scholar
• van der Hoek J, Waaijers M, van Koetsveld PM et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am. J. Physiol. Endocrinol. Metab.289(2), E278–E287 (2005).
   PubMed Web of Science ®Google Scholar
• Strowski MZ, Dashkevicz MP, Parmar RM et al. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology6, 339–346 (2002).
   Google Scholar
• Cervia D, Nunn C, Fehlmann D, Langenegger D, Schuepbach E, Hoyer D. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br. J. Pharmacol.1, 109–121 (2003).
   Google Scholar
• Hofland LJ, van der Hoek J, Feelders R et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur. J. Endocrinol.152(4), 645–654 (2005).
   PubMed Web of Science ®Google Scholar
• Batista DL , Zhang X, Gejman R et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J. Clin. Endocrinol. Metab.91(11), 4482–4488 (2006).
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol.146(5), 707–716 (2002).
   PubMed Web of Science ®Google Scholar
• Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur. J. Endocrinol.153(3), R7–R10 (2005).
   Web of Science ®Google Scholar
• Boscaro M, Petersenn S, Atkinson AB et al. Pasireotide (SOM230), the novel multi-ligand somatostatin analogue, is a promising medical therapy for patients with Cushings disease: preliminary safety and efficacy results of a Phase II study. Proceedings of the Endocrine Society’s 88th Annual Meeting. Boston, MA, USA 24–27 June 2006 (Abstract OR9–1).
   Google Scholar
• Unger N, Helmut T, Schultz S, Wolfgang S, Klaus M, Petersenn S. Differential expression of somatostatin receptor subtypes 1–5 proteins in numerous normal human tissues. European Congress of Endocrinology (Abstract P1–192) (2005).
   Google Scholar
• Paez-Pereda M, Kovalovsky D, Hopfner U et al. Retinoic acid prevents experimental Cushing syndrome. J. Clin. Invest.108(8), 1123–1131 (2001).
   PubMed Web of Science ®Google Scholar
• Lauber M, Theodoropoulou M, Sievers C. New aspects in the diagnosis and treatment of Cushing disease. Front. Horm. Res.35, 169–178 (2006).
   PubMed Web of Science ®Google Scholar
• Castillo V, Giacomini D, Paez-Pereda M et al. Retinoic acid as a novel medical therapy for Cushing’s disease in dogs. Endocrinology147(9), 4438–4444 (2006).
   PubMed Web of Science ®Google Scholar
• Luton JP, Mahoudeau JA, Bouchard P et al. Treatment of Cushing’s disease by O,p’DDD. Survey of 62 cases. N. Engl. J. Med.300(9), 459–464 (1979).
   PubMed Web of Science ®Google Scholar
• Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing’s syndrome: experience in 34 patients. Clin. Endocrinol. (Oxford)35(4), 347–352 (1991).
   PubMed Web of Science ®Google Scholar
• Stiefel P, Garcia-Morillo JS, Jimenez L et al. Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in non ectopic Cushing’s syndrome. Endocrine18(3), 279–284 (2002).
   Google Scholar
• Smagin GN, Goeders NE. Effects of acute and chronic ketoconazole administration on hypothalamo–pituitary–adrenal axis activity and brain corticotropin-releasing hormone. Psychoneuroendocrinology29(10), 1223–1228 (2004).
   Google Scholar
• Deuschle M, Lecei O, Stalla GK et al. Steroid synthesis inhibition with ketoconazole and its effect upon the regulation of the hypothalamus–pituitary–adrenal system in healthy humans. Neuropsychopharmacology28(2), 379–383 (2003).
   Google Scholar
• Boscaro M, Sonino N, Rampazzo A, Mantero F. Response of pituitary–adrenal axis to corticotrophin releasing hormone in patients with Cushing’s disease before and after ketoconazole treatment. Clin. Endocrinol. (Oxford)27(4), 461–467 (1987).
   PubMed Web of Science ®Google Scholar
• Inagaki M, Akizuki N, Kugaya A, Fujii H, Akechi T, Uchitomi Y. Metyrapone for Cushing’s syndrome. Am. J. Psychiatry159(7), 1246 (2002).
   Google Scholar
• Beardwell CG, Adamson AR, Shalet SM. Prolonged remission in florid Cushing’s syndrome following metyrapone treatment. Clin. Endocrinol. (Oxford)14(5), 485–492 (1981).
   Google Scholar
• Sonino N, Boscaro M, Ambroso G, Merola G, Mantero F. Prolonged treatment of Cushing’s disease with metyrapone and aminoglutethimide. IRCS Med. Sci.14, 485–486 (1986).
   Google Scholar
• Cheng VY, Martin LJ, Elliott EM et al. α5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J. Neurosci.26(14), 3713–3720 (2006).
   PubMed Web of Science ®Google Scholar
• Li GD, Chiara DC, Sawyer GW, Husain SS, Olsen RW, Cohen JB. Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. J. Neurosci.26(45), 11599–11605 (2006).
   Google Scholar
• Zeller A, Arras M, Jurd R, Rudolph U. Mapping the contribution of β3-containing GABAA receptors to volatile and intravenous general anesthetic actions. BMC Pharmacol.7, 2 (2007).
   Google Scholar
• Allolio B, Schulte HM, Kaulen D, Reincke M, Jaursch-Hancke C, Winkelmann W. Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing’s syndrome. Klin. Wochenschr.66(8), 361–364 (1988).
   PubMedGoogle Scholar
• Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing’s syndrome and doseresponse relationship in normal subjects. J. Clin. Endocrinol. Metab.70(5), 1426–1430 (1990).
   PubMed Web of Science ®Google Scholar
• Greening JE, Brain CE, Perry LA et al. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing’s disease. Horm. Res.64(3), 140–143 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson TN, Canada TW. Etomidate use for Cushing’s syndrome caused by an ectopic adrenocorticotropic hormone-producing tumor. Ann. Pharmacother.41(2), 350–353 (2007).
   PubMed Web of Science ®Google Scholar
• Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing’s syndrome. J. Clin. Endocrinol. Metab.86(9), 4104–4108 (2001).
   PubMed Web of Science ®Google Scholar
• Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing’s syndrome and peritonitis. J. Clin. Endocrinol. Metab.83(10), 3542–3544 (1988).
   Google Scholar
• Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486). J. Clin. Endocrinol. Metab.86(8), 3568–3573 (2001).
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing’s syndrome. N. Engl. J. Med.352(23), 2457–2458 (2005).
   PubMed Web of Science ®Google Scholar